TCF responsive element
US6608037B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2001 |
| Grant date | Aug 19, 2003 |
| Priority date | — |
| Expiry date | Mar 2, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/85
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are DNA elements and constructs useful for obtaining tumour-selective gene expression in tumours having a mutated &bgr;-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumour cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumour cells can be demonstrated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.